Latest news with #ARS
Yahoo
20-05-2025
- Business
- Yahoo
Advance Relocation Systems Welcomes Nicolle Barbour To The Team
Her Addition Strengthens Their Commitment to Excellence in Global Logistics. ABINGDON, Md., May 20, 2025 /PRNewswire/ -- Advance Relocation Systems is pleased to have Nicolle Barbour, a.k.a. Nikki, who recently returned to the organization, as the Sales and Marketing expert. Having three decades of experience in international logistics and government-contracted shipments, she is bringing a wealth of knowledge back to the team. Her journey, values and accomplishments makes Nikki a really valuable addition to the ARS family. A Familiar Face with Extensive ExpertiseNikki's journey with ARS first began 30 years ago, shortly after she graduated from college. After a successful career as a teacher and then working in international logistics and government contracts, she returned to ARS in March 2025. Nikki specializes in government-contracted shipments, particularly for SOFA-status employees, handling everything from international moves to complex interstate logistics. She offers a fresh perspective to ARS while enhancing the services that the company provides to clients worldwide. Driving Change Through Process ImprovementIn her role at ARS, Nikki is focused on refining processes and improving efficiency. With remarkable organizing skills and an eye for detail, she is working towards streamlining operations and ensuring that clients receive the best quality service. It is this drive and commitment to excellence that makes her an invaluable member of the ARS team. Her dedication to continuous improvement is evident, and her proactive approach is bound to make a significant impact on the team. "My ultimate goal is to be able to come up with a better, more streamlined, more detailed way of taking care of our customers, processing the information, how it's kept within our company and how it's accessed." - Nicolle Barbour, Sales and Marketing Expert, Advance Relocation Systems. Family, Integrity, and a Passion for LifeOutside of work, Nikki is a family-oriented individual who enjoys spending time with her husband and two sons. Family has always been a central part of her life, and she greatly appreciates the moments spent together. Travel, music and cooking are just a few of her favorite pastimes, and she is passionate about helping animals in need. Her stepfather, who taught her the importance of integrity, has been one of the most influential figures in her life. Nikki upholds honesty, integrity and humility as the most important values in life. This guides her personally and professionally. "You have nothing if you don't have your integrity" - Nicolle Barbour, Sales and Marketing Expert, Advance Relocation Systems. Known for her nurturing and organized nature, Nikki is selfless and always considers the needs and feelings of others before her own. ARS is thankful to have her back on the team, and looks forward to all the great things she will continue to contribute. Advance Relocation Systems has been delivering long-distance and international moves seamlessly. The company attributes its success to the invaluable people on the team. About Advance Relocation SystemsAdvance Relocation Systems is a national moving company based in Maryland. For more than 85 years, they have helped countless customers relocate their homes and businesses. They possess a fleet of almost 100 vehicles and a 62,000-square-foot warehouse storage facility. This, coupled with their membership in the Atlas® Van Lines global network means they have all the necessary resources to take on even the largest, most complex moves while still focusing on safety and personal customer service. For more information, Contact ARS. [Social Media Handles] Instagram - - - - View original content to download multimedia: SOURCE Advance Relocation Systems Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
16-05-2025
- Business
- Time of India
Page Industries, Bharti Airtel & more: Top stocks on brokers' radar for May 16, 2025
Motilal Oswal Financial Services has a buy recommendation on Page Industries with the target price at Rs 57,500. Analysts said that the company showed strong volume growth with robust margin expansion during the Jan-March quarter. Analysts also model an EBIDTA margin guidance at the higher end of the 19%-21% range for FY26. They feel there is still upside risk due to strong gross margin recovery. In addition, they also feel the company's initiations towards inventory optimization through the ARS system, new product launches, capacity expansion, and digitization initiatives will support growth. BNP Paribas has an outperform rating for Bharti Airtel with the target price at Rs 2,000. Analysts said Airtel reported strong numbers for the Jan-March period with its India mobile revenue, EBITDA and operating cash flow growing strongly. Results were largely in-line, excluding favourable exceptionals. Airtel doubled its dividend y-y, and with strong cash generation ahead, we see scope for further increases. While overall capex is set to decline, Airtel is looking to invest in high-growth areas such as home broadband, enterprise and digital while reducing subsidies in the low-growth DTH business. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 牛乳メーカーが遂に発見！骨密度を半年で高めたことが確認された成分 雪印メグミルク Undo Elara Securities India has a buy rating on REC with the target price at Rs 650, but has reduced EPS estimates. Analysts said this was on the back of lower growth during recent months. They said REC's growth run-rate has slowed on a high asset base and recoveries. Healthy NIMs continue to aid earnings. The company is now a steady compounder with long-term growth. ICICI Securities has an add rating on Akzo Nobel with the target price at Rs 3,700. Analysts feel Akzo Nobel's premium/luxury positioning drove market share gain for the third year running. While the paint industry contracted in FY25 and Birla Opus also grabbed a low-mid single market share in FY25, Akzo performed well with market share gains in all four quarters of FY25. Akzo has done healthy investments in product differentiation and distribution but they believe the chief reason for market share gain is premium/ luxury positioning. In their view, the price conscious consumers are likely to be swayed away by new brands offering higher trade discounts/schemes. They also believe Akzo Nobel is in a better position to maintain its margins compared to its peers. Emkay Global Financial Services has an add rating on Jubilant Foodworks with the target price at Rs 775. Analysts said the company's Jan-March performance was in-line with their estimates. The company continued to outperform in the Jan-march quarter too, helped by company-specific initiatives in terms of free/faster deliveries, new innovations and organizational restructuring, as broader demand remains weak. With launch of Big-Big-Pizza and anniversarization of delivery waiver, bill size has reverted to growth in the current quarter and should help deliver mid-teens growth in FY26. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
16-05-2025
- Business
- Time of India
Top stocks to buy today: Stock recommendations for May 16, 2025
Motilal Oswal Financial Services has a buy recommendation on Page Industries with the target price at Rs 57,500. Analysts said that the company showed strong volume growth with robust margin expansion during the Jan-March quarter. Analysts also model an EBIDTA margin guidance at the higher end of the 19%-21% range for FY26. They feel there is still upside risk due to strong gross margin recovery. In addition, they also feel the company's initiations towards inventory optimization through the ARS system, new product launches, capacity expansion, and digitization initiatives will support growth. BNP Paribas has an outperform rating for Bharti Airtel with the target price at Rs 2,000. Analysts said Airtel reported strong numbers for the Jan-March period with its India mobile revenue, EBITDA and operating cash flow growing strongly. Results were largely in-line, excluding favourable exceptionals. Airtel doubled its dividend y-y, and with strong cash generation ahead, we see scope for further increases. While overall capex is set to decline, Airtel is looking to invest in high-growth areas such as home broadband, enterprise and digital while reducing subsidies in the low-growth DTH business. Elara Securities India has a buy rating on REC with the target price at Rs 650, but has reduced EPS estimates. Analysts said this was on the back of lower growth during recent months. They said REC's growth run-rate has slowed on a high asset base and recoveries. Healthy NIMs continue to aid earnings. The company is now a steady compounder with long-term growth. ICICI Securities has an add rating on Akzo Nobel with the target price at Rs 3,700. Analysts feel Akzo Nobel's premium/luxury positioning drove market share gain for the third year running. While the paint industry contracted in FY25 and Birla Opus also grabbed a low-mid single market share in FY25, Akzo performed well with market share gains in all four quarters of FY25. Akzo has done healthy investments in product differentiation and distribution but they believe the chief reason for market share gain is premium/ luxury positioning. In their view, the price conscious consumers are likely to be swayed away by new brands offering higher trade discounts/schemes. They also believe Akzo Nobel is in a better position to maintain its margins compared to its peers. Emkay Global Financial Services has an add rating on Jubilant Foodworks with the target price at Rs 775. Analysts said the company's Jan-March performance was in-line with their estimates. The company continued to outperform in the Jan-march quarter too, helped by company-specific initiatives in terms of free/faster deliveries, new innovations and organizational restructuring, as broader demand remains weak. With launch of Big-Big-Pizza and anniversarization of delivery waiver, bill size has reverted to growth in the current quarter and should help deliver mid-teens growth in FY26. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Yahoo
13-05-2025
- Health
- Yahoo
US farm agency staff warn Congress of food safety risks, political interference
By Leah Douglas WASHINGTON (Reuters) -Unions representing staff in the U.S. Department of Agriculture's research, animal health and nutrition agencies warned lawmakers of political interference and irreparable damage to their work from President Donald Trump's efforts to shrink the federal government in a letter sent on Monday night. More than 15,000 USDA staff have been fired or accepted Trump's financial incentives to leave the agency, leaving fewer experts to respond to an ongoing outbreak of bird flu and draining technical staff from local offices that serve farmers. Trump's proposed budget would cut $4.5 billion from the USDA, including from conservation and research programs. Agriculture Secretary Brooke Rollins has defended the cuts as efficient. "The combination of harmful budget cuts, executive overreach, and politically motivated staffing changes have weakened key agencies," said the letter from 20 officials of USDA staff unions and sent to the chairs and ranking members of the Senate and House appropriations committees that oversee the agency. "Without Congressional oversight, the decades of knowledge and infrastructure that ensure food safety and security will be dismantled." The USDA did not immediately respond to a request for comment. Across the USDA's Agricultural Research Service, 98 of 167 food safety scientists have resigned, according to the letter. The ARS's work includes detecting pathogens, preventing foodborne illness, and identifying chemical and other contaminants in food, according to the USDA website. Researchers have been barred from travel to conferences and staff attrition has hobbled work on climate adaptation, hunger and fraud prevention in nutrition programs, the letter said. Scientists have been told not to discuss agency staffing losses or research cuts with external stakeholders and face ambiguity about what public activities are permitted, said Ethan Roberts, a technician at an ARS lab in Illinois and president of the American Federation of Government Employees Local 3247. "The only way that you can learn about what truly is and is not allowed is by doing it and getting punished or reprimanded," Roberts said. In addition to AFGE, the staff unions are represented by the National Treasury Employees Union and the American Federation of State, County and Municipal Employees.
Business Wire
13-05-2025
- Business
- Business Wire
Tivic Expands VNS Intellectual Property Portfolio
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled ' Vagus Nerve Stimulation System ' expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus nerve stimulation. 'We continue to build a defensible position for our next generation VNS technology,' said Blake Gurfein, Tivic Chief Scientific Officer. 'This patent protects key learnings from our VNS optimization study, which is advancing the science of vagus nerve interventions. In fact, we believe we are moving the needle on what will become the state-of-the art treatment approach by delivering much greater and more consistent therapeutic effects compared to what is currently available.' Jennifer Ernst, Tivic CEO, stated, 'As we continue to advance our VNS program, protecting our proprietary and intellectual property is critical. Tivic's diversified portfolio of bioelectronic VNS and biologic immunotherapies represent a unique breadth of treatments to address health issues where immune system dysregulation is a significant underlying factor.' About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation for the vagus nerve to deliver meaningful improvements in clinically relevant measures of the autonomous nervous system compared to current treatments, which are often invasive, ineffective or both. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's first FDA approved product ClearUP™ is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the future development of ncVNS treatment, the Tivic Health's ability to commercialize products arising out of the ncVNS treatment and the Tivic Health's plans to seek regulatory approval for such clinical products and Tivic Health's continued focus on developing ncVNS treatment, including in the epilepsy, post-traumatic stress disorder, and/or ischemic stroke space; expected clinical utility including which patient populations may be pursued; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health's capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health's actual results to differ from those contained in the forward-looking statements, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading 'Risk Factors'; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
